ReviewPharmaceutics2025
The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- 3D-printed polypills for personalized medicine and precision oral drug delivery in pharmaceutical practice: A review.International journal of pharmaceutics: X · 2026Review
- Review
- Innovative advances and future perspectives in injectable hydrogels for wound healing: a comprehensive review.Biomedical engineering online · 2026Review
- Dose Accuracy and Content Uniformity of Low-Dose Metoprolol Tablets: 3D Printing Compared with Tablet Splitting in Hospital Pharmacy Setting.Pharmaceutics · 2026Article
- Volumetric Control vs. Pneumatic Pressure: A Comparative Analysis of Extrusion in 3D Bioprinting.Micromachines · 2026Article
- 3D Printed Vaginal Rings For Contraceptive Applications: Materials, Mechanisms, and Opportunities.AAPS PharmSciTech · 2026Review
- Design of Experiments in the Formulation and Characterization of 3D-Printed Vaginal Films Loaded with Curcumin Solid Lipid Nanoparticles for Cervical Dysplasia.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Digital Manufacturing of Calcium Phosphate-Based Dental Materials: From Design to Clinical Use.Materials (Basel, Switzerland) · 2026Review
- Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.International journal of nanomedicine · 2026Review
- Current 3D Printing Technologies and their Potential Applications in Drug Delivery, Personalized Medicine & Pharmaceutical Sciences.Current drug discovery technologies · 2026Review
- Building the next frontier: Artificial intelligence in 3D-printed medicines.Biomaterials translational · 2026Review
- Three-Dimensionally Printed Paediatric Medicines: Formulation, Process, and Regulatory Considerations.Pharmaceutics · 2025Review
- Beyond Dysphagia in Parkinson's Disease: 3D Printing of Orally Disintegrating Tablets (ODTs) for Optimized Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Development of an efficient approach to boost fused deposition modeling (FDM) printing of felodipine-HPMC tablets for enhanced physical stability.International journal of pharmaceutics: X · 2025Article
- Personalized Vaginal Drug Delivery through 3D Printing: Techniques, Challenges, and Future Perspectives.AAPS PharmSciTech · 2025Review
- High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy.Current oncology (Toronto, Ont.) · 2025Review
- Pharmaceutical 3D Printing for Psychiatric Medications: Advanced Innovations in Taste Masking and Personalized Oral Drug Delivery.Pharmaceutical research · 2025Review
- Tailoring Therapy: Hydrogels as Tunable Platforms for Regenerative Medicine and Cancer Intervention.Gels (Basel, Switzerland) · 2025Review
- Mechanobiology in Action: Biomaterials, Devices, and the Cellular Machinery of Force Sensing.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Three-dimensional printing technology is transforming pharmaceutical manufacturing by shifting from conventional mass production to additive manufacturing, with a strong emphasis on personalized medicine. The integration of bioinks and AI-driven optimization is further enhancing this innovation, enabling drug production with precise dosages, tailored drug-release profiles, and unique multi-drug combinations that respond to individual patient needs. This advancement is significantly impacting healthcare by accelerating drug development, encouraging innovative pharmaceutical designs, and enhancing treatment efficacy. Traditional pharmaceutical manufacturing follows a one-size-fits-all approach, which often fails to meet the specific requirements of patients with unique medical conditions. In contrast, 3D printing, coupled with bioink formulations, allows for on-demand drug production, reducing dependency on large-scale manufacturing and storage. AI-powered design and process optimization further refine dosage forms, printability, and drug release mechanisms, ensuring precision and efficiency in drug manufacturing. These advancements have the potential to lower overall healthcare costs while improving patient adherence to medication regimens. This review explores the potential, challenges, and environmental benefits of 3D pharmaceutical printing, positioning it as a key driver of next-generation personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.